Allergy Therapeutics announced on 26 November that it intends to carry out a smaller trial of Grass MATAMPL in the US/Europe to determine whether the learnings from its failed Phase III trial of PQ Birch can be successfully applied to the Grass study, after which it will run the larger pivotal Phase III trial for registration purposes. This two-step approach adds an additional year to the development programme but should improve the probability of success and ensure that the more substantial ....